Table 2.
Clinical data of patients with Graves’ ophthalmopathy, patients with Graves’ disease and healthy controls.
| GO | GD | N | |
|---|---|---|---|
| T3(pmol/L) | 3.17(0.95,5.92) | 3.51(1.23,6.53) | 1.28(0.62,2.67)b,c |
| T4(pmol/L) | 142.28(68.30,196.60) | 159.02(28.80,274.10) | 67.86(58.92,130.59)b,c |
| FT3(pmol/L) | 9.18(3.11,18.95) | 11.26(3.80,27.62) | 4.96(3.35,6.29)b,c |
| FT4(pmol/L) | 25.83(13.06,40.91) | 27.09(12.71,52.08) | 13.4(9.72,17.41)b,c |
| TSH(uIU/ml) | 0.02(0.00,0.11) | 0.02(0.00,0.14) | 2.1(1.06,3.60)b,c |
| TPOAb(IU/ml) | 70.56(10.33,150.94) | 82.49(9.74,140.81) | 20.83(5.33,35.13)b,c |
| TGAb(IU/ml) | 261.54(10.10,1231.00) | 304.09(10.82,1402.00) | 48.17(3.09,100.38)b,c |
| TRAb(IU/L) | 11.40(2.38,35.75) | 8.78(1.51,24.96)a | 0.38(0.3,0.93)b,c |
| ALT(U/L) | 16.13(8,29) | 20.57(8,36) | 21.80(9,37) |
| AST(U/L) | 18.6(12,29) | 19.68(12,35) | 21.05(14,40) |
| BUN(mmol/L) | 4.74(2.6,6.5) | 4.75(2.6,9.1) | 5.52(2.5,9.6) |
| CREA(umol/L) | 61.67(50,70.6) | 63.74(50,94) | 68.01(48,93.6) |
| Tear volume(mm/eye) | 14.5(5,30) | 11.6(5.5,30) | 12.3(5,30) |
The values are the mean (SD), median (range), or n (%). Comparison between any two groups was performed by Mann–Whitney U test. aP < 0.05 between patients with Graves’ ophthalmopathy and Graves’ disease; bcP < 0.001 healthy controls compared with patients with Graves’ ophthalmopathy or Graves’ disease. CAS, clinical activity score; NOSPECS, no signs or symptoms, only signs, soft tissue, proptosis, extraocular muscle, cornea, sight loss; TSH, thyroid-stimulating hormone; TPOAb, thyroperoxidase antibody; TGAb, antithyroglobulin antibody; TRAb, thyrotropin receptor antibody. Normal ranges: T3 0.92-2.79nmol/L, T4 57.9-140.3nmol/L, FT3 3.5-6.5pmol/L, FT4 11.5-22.7pmol/L, TSH 0.55-4.78uIU/ml, TPOAb 0-40 IU/ml, TGAb 0-115IU/ml, TRAb 0-1.75IU/L.